country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P12375

Copy Link Print Information

B18 peptide

B18 peptide is a cationic amphipathic α-helical peptidomimetic that binds to the BST-2 extracellular domain and forms a stable complex through intermolecular hydrogen bonds near the N-terminus. B18 peptide competitively inhibits the binding of BST-2 to the extracellular matrix via its extracellular domain, reducing migrasome formation. B18 peptide induces membrane lysis through the formation of pores/water channels and annular pores, impairing membrane integrity. B18 peptide exhibits anticancer activity against breast cancer. B18 peptide can be used for research on breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3027663-77-7
Formel: C₇₈H₁₂₁N₂₃O₂₈S₂
Molecular Weight:1893.06

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

B18 peptide Chemical Structure

CAS. Nr.: 3027663-77-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC50	59.8 μM	Cytotoxicity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay. Cytotoxicity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.	32155736
SK-BR-3	IC50	11.2 μM	Cytotoxicity against human SKBR3 breast cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay. Cytotoxicity against human SKBR3 breast cancer cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.	32155736

In Vitro

Anti-cancerOthers

Anti-cancer

B18 peptide (0.5-132.0 μM; 24 h) exhibited selective cytotoxic effects, reducing the viability of MCF7 and SKBR3 breast cancer cells, while showing no cytotoxic effects on MDA-MB-231, MDA-MB-468, T47D, and ZR-75-1 cells, and enhanced the viability of PBMCs at high concentrations^[3].

Others

B18 peptide significantly reduces migrasome formation by competitively inhibiting BST2-mediated extracellular matrix adhesion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[3]

Cell Line:

MCF7, SKBR3, MDA-MB-231, MDA-MB-468, T47D, ZR-75-1, and human PBMCs
Concentration:

0, 0.5, 1.0, 2.1, 4.1, 8.3, 16.5, 33.0, 66.0, 132.0 μM
Incubation Time:

24 h
Result:

Reduced cell viability for MCF7 and SKBR3 cell lines with IC₅₀ values of 59.8 μM and 11.2 μM, respectively.
No significant loss of viability was observed for MDA-MB-231, MDA-MB-468, T47D, and ZR-75-1 cell lines, even at the highest concentration tested.
No cytotoxic effect was observed for quiescent human PBMCs; however, at concentrations of 66.0 and 132.0 μM, B18 enhanced cell viability.
Subtle increases in viability were also observed in T47D cells.

Related Protocols :

Chemical Information

CAS. Nr. 3027663-77-7
Molecular Weight 1893.06
Formel C₇₈H₁₂₁N₂₃O₂₈S₂
SMILES

O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CS)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CNC=N2)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@@H](CCSC)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN
Sequence

Gly-Phe-Gln-Asp-Val-Glu-Ala-Gln-Ala-Ala-Thr-Cys-Asn-His-Thr-Val-Met-Ala
Sequence Shortening

GFQDVEAQAATCNHTVMA
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Lyu Y, et al. Development of a Cationic Amphiphilic Helical Peptidomimetic (B18L) As A Novel Anti-Cancer Drug Lead. Cancers. 2020 Aug 28;12(9):2448.

[2]. Li X, et al. GPI‑anchored protein nanoclusters license migrasome expansion and serve as exocytic platforms for migrasome. Nat Commun. 2026 Jun 4;17(1):7162. [Content Brief]

[3]. Lyu Y, et al. Development and Characterization of the Shortest Anti-Adhesion Peptide Analogue of B49Mod1. Molecules (Basel, Switzerland). 2020 Mar 06;25(5):1188.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen